Treatment

Semaglutide 1.0 mg clinical trials

Active studies that list Semaglutide 1.0 mg as an intervention or treatment.

4active studies

1recruiting now

2countries represented

1largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 1

Alcohol Use Disorder, Weight LossCondition

Semaglutide 1.0 mgTreatment

United States1 locations

Yale UniversitySponsor

Updated 2026-05-12 · NCT07223983See eligibility →

Opening soonPhase 1

Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)Condition

Placebo, Semaglutide 1.0 mgTreatment

United States1 locations

Yale UniversitySponsor

Updated 2026-08-19 · NCT07772960See eligibility →

Opening soonPhase 4

Psoriasis ArthritisCondition

Semaglutide 0.5 mg, Semaglutide 1.0 mgTreatment

Locations pending0 locations

Chinese University of Hong KongSponsor

Updated 2025-12-02 · NCT07251556See eligibility →

Opening soonPhase 4

Glucagon-Like Peptide-1 Receptor Agonists, Type 2 DiabetesCondition

Semaglutide 1.0 mg, Semaglutide 0.5 mgTreatment

Taiwan1 locations

Taipei Veterans General Hospital, TaiwanSponsor

Updated 2025-07-18 · NCT07073053See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.